|
Subho Chakrabarti describes for SIIC the most significant aspects of his article describe para SIIC los aspectos relevantes de su artículo Adherence and persistence with first and second generation antipsychotic treatment. Medication-adherence and persistence with first- and second-generation antipsychotics in schizophrenia Whether medication-adherence differs between patients on first-generation (FGAs) and second-generation antipsychotics (SGAs) is unresolved despite considerable research. Medication-adherence and persistence was compared between patients with schizophrenia on SGAs and FGAs over six months. Patients on SGAs, particularly olanzapine were more likely to persist with their treatment that those on FGAs. The article was published by El artículo fue publicado por
Principal institution where the research took place Institución principal de la investigación Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, UT, Chandigarh, India  Authors' Report Crónica del Autor
Adhesión y Persistencia del Tratamiento con Antipsicóticos de Primera y Segunda Generación
Bibliographic references Adhesión Farmacológica y Continuidad del Tratamiento con Antipsicóticos de Primera y Segunda Generación en la Esquizofrenia Las posibles diferencias en la adhesión al tratamiento con antipsicóticos de primera y segunda generación (APG y ASG, respectivamente), en sujetos con esquizofrenia, han sido muy estudiadas pero todavía se conocen poco. La adhesión a las drogas y la continuidad del tratamiento se compararon entre pacientes con esquizofrenia tratados con APG y ASG en un período de seis meses. Los pacientes que recibieron ASG, especialmente olanzapina, tuvieron más probabilidades de mantener el tratamiento, en comparación con los enfermos tratados con APG. Crónica del Autor Imprimir nota Referencias bibliográficas Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull 23:637-51, 1997. Foussias G, Remington G. Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making. Can J Psychiatry 55:117-25, 2010. Awad GA. Antipsychotic medications: Compliance and attitudes towards treatment. Curr Opin Psychiatry 17:75-80, 2004. Voruganti LP, Baker LK, Awad AG. New generation antipsychotic drugs and compliance behaviour. Curr Opin Psychiatry 21:133-9, 2008. Ascher-Svanum H, Zhu B, Faries DE, Lacro JP, Dolder CR, Peng X. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence 2:67-7, 2008. Janssen B, Gaebel W, Haerter M, Komaharadi F, Lindel B, Weinmann S. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology (Berl) 187:229-36, 2006. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: Can we resolve the conflict? Psychol Med 39:1591-602, 2009. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-23, 2005. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost utility of the latest antipsychotic drugs in Schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63:1079-87, 2006. Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results. Eur Neuropsychopharmacol 17:235-44, 2007. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 371:1085-97, 2008. Agius M, Davis A, Gilhooley M, Chapman S, Zaman R. What do large scale studies of medication in schizophrenia add to our management strategies? Psychiatr Danub 22:323-8, 2010. Haynes RB, Taylor DW, Sachett DL. Compliance in Health Care. Baltimore: John Hopkins University Press, 1979. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: Terminology and definitions. Value Health 11:44-7, 2008. Cooper D, Moisan J, Grégoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: A population-based study in schizophrenia. J Clin Psychiatry 68:818-25, 2007. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 161:692-9, 2004. Kelin K, Lambert T Jr, Brnabic AJ, Newton R, Ye W, Escamilla RI, et al. Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence. Patient Prefer Adherence 5:213-22, 2011. Other articles written by the author Subho Chakrabarti Otros artículos de Subho Chakrabarti Chakrabarti S, Kulhara P, Verma SK. Extent and determinants of burden among families of patients with affective disorders. Acta Psychiatrica Scandinavica 86:247-252, 1992. Chakrabarti S, Gill S. Coping and its correlates among caregivers of patients with bipolar disorder: a preliminary study. Bipolar Disorders 4:50-60, 2002. Nehra R, Chakrabarti S, Kulhara P, Sharma R. Caregiver-coping in bipolar disorder and schizophrenia: a re-examination. Social Psychiatry and Psychiatric Epidemiology 40:329-336, 2005. Nehra R, Chakrabarti S, Pradhan BK, Khehra N. Comparison of cognitive functions between first- and multi-episode bipolar affective disorders. Journal of Affective Disorders 93:185-192, 2006. Grover S, Avasthi A, Chakrabarti S, Bhansali A, Kulhara P. Cost of care of schizophrenia: A study of Indian outpatient attenders. Acta Psychiatrica Scandinavica 112:54-63, 2005. Kulhara P, Chakrabarti S. Culture and schizophrenia and other psychotic disorders. Psychiatric Clinics of North America 24:449-464, 2001. Grover S, Kumar V, Chakrabarti S. Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research 71:277-281, 2011. Chakrabarti S, Kulhara P, Verma SK The pattern of burden in families of neurotic patients. Social Psychiatry and Psychiatry Epidemiology 28:172-177, 1993. Kulhara P, Chakrabarti S, Avasthi A, Sharma A, Sharma S. Psychoeducational intervention for caregivers of Indian patients with schizophrenia: a randomised-controlled trial. Acta Psychiatrica Scandinavica 119:472-483, 2009. Chakrabarti S. Thyroid functions and bipolar affective disorder. Journal of Thyroid Research 2011:1-13, 2011. SIIC System of Assisted Editing (SSEA) / Sistema SIIC de Edición Asistida (SSEA)
The article is strictly related to the following sections of siicsalud El artículo se relaciona estrictamente con las siguientes secciones de siicsalud
Information about the full text Acerca del trabajo completo Adherence and Continuation of Treatment with First- and Second-Generation Antipsychotics in Schizophrenia Author / Autor Nisha Warikoo1 1 Dr, Department Of Psychiatry, Postgraduate Institute Of Medical Education And Research, Chandigarh, India, Chandigarh, India, Formerly Junior Resident Access to the original source Indian Journal of Psychological Medicine siic DB: / siic DB: http://www.siicsalud.com/main/distriprinrel.php |
|||||||||||||||||||||||
Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008
